絶え間ないまたは周期的な混乱下にある腫瘍宿主システムの競争的なロトカ-ヴォルテラモデルのダイナミクス:癌の治療への影響
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。この研究では,Lotka-Volterra方程式を用いて腫瘍-宿主ダイナミクスをモデル化しています. 免疫療法のような低頻度定期的な治療は,宿主の動態に影響を与えることで,攻撃的な腫瘍を制御することができます.
科学分野
- 数学的な腫瘍学
- システム生物学
- 腫瘍の動態
背景
- 腫瘍と宿主の相互作用は複雑で 癌の進行には極めて重要です
- これらのダイナミクスを理解することは 効果的ながん治療法の開発の鍵です
- 現在の治療法では 攻撃的な腫瘍を完全に根絶することは困難です
研究 の 目的
- 腫瘍と宿主の相互作用を モデル化するために ロッカ-ヴォルテラ・フレームワークを使用します
- 周期的な混乱が腫瘍の動態に与える影響を分析する.
- 攻撃的な腫瘍を制御するための最適な治療戦略を決定する.
主な方法
- 腫瘍-宿主ダイナミクスを用いた ロトカ-ヴォルテラ数学的モデル
- 臨界パラメータとダイナミックレジームを特定するために線形安定性分析を行いました.
- 恒定と周期的な乱れがシステムに与える影響を調べた.
- 望むシステム状態に必要な治療用量を計算する.
主要な成果
- 腫瘍-宿主ダイナミクスを支配する重要なパラメータを特定した.
- 低頻度の定期的な治療では,攻撃的な腫瘍が限界サイクルへと進化することを示した.
- 治療頻度が増加するにつれて,非混沌のアトラクターへの移行が観察されました.
- Lyapunov指数で 混沌とした行動がないことを確認しました
結論
- 侵襲的な腫瘍は,従来の治療法で完全に根絶できず,制御可能である.
- 免疫療法のような宿主を標的とした低頻度定期的な治療は,腫瘍制御の可能性を示しています.
- 腫瘍の動態を安定させ 新しい治療方法を示唆します
関連する概念動画
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Tumors may result in a case where two people have the same mutations in an oncogene or tumor...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...